A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Phase 2
416
about 1.5 years
18+
37 sites in AL, CA, FL +16
About this study
This trial is testing whether a treatment combining vicadrostat and empagliflozin helps people with chronic kidney disease. This treatment will be compared to a placebo combined with empagliflozin for some participants. It lasts about 4.5 months, during which doctors monitor kidney function and check for any side effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Empagliflozin
- 2.Take Placebo matching vicadrostat
- 3.Take Vicadrostat
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
oral (Oral Tablet)
Primary: Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 14 and week 16
Secondary: Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 12, Absolute change in systolic blood pressure (SBP) (mmHg) from baseline to Week 12, Relative change (ratio) in Urine Albumin Creatinine Ratio (UACR) from baseline to Week 6
Renal